I'm LongbridgeAI, I can summarize articles.Q2 2026 saw a net loss of $42.7M and $4.6M in collaboration revenue from the Overland license termination. Cash and investments totaled $423.6M, supporting operations into Q1 2029. Key clinical programs advanced, with cema-cel receiving RMAT and Fast Track designations.Original document: Allogene Therapeutics, Inc. [ALLO] SEC 10-Q Quarterly Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw a net loss of $42.7M and $4.6M in collaboration revenue from the Overland license termination. Cash and investments totaled $423.6M, supporting operations into Q1 2029. Key clinical programs advanced, with cema-cel receiving RMAT and Fast Track designations.
Original document: Allogene Therapeutics, Inc. [ALLO] SEC 10-Q Quarterly Report — Aug. 12 2026